<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Neurol</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Neurology</journal-title></journal-title-group><issn pub-type="ppub">2168-6149</issn><issn pub-type="epub">2168-6157</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11320331</article-id><article-id pub-id-type="pmcid-ver">PMC11320331.1</article-id><article-id pub-id-type="pmcaid">11320331</article-id><article-id pub-id-type="pmcaiid">11320331</article-id><article-id pub-id-type="pmid">39133474</article-id><article-id pub-id-type="doi">10.1001/jamaneurol.2024.2404</article-id><article-id pub-id-type="publisher-id">noi240047</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="featured" specific-use="electronic"><subject>Featured</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke</article-title><subtitle>A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial</subtitle><alt-title alt-title-type="headline">Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke</alt-title><alt-title alt-title-type="running-head">Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Navi</surname><given-names initials="BB">Babak B.</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="noi240047aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="noi240047aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="C">Cenai</given-names></name><degrees>MS</degrees><xref rid="noi240047aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Miller</surname><given-names initials="B">Benjamin</given-names></name><degrees>MD</degrees><xref rid="noi240047aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cushman</surname><given-names initials="M">Mary</given-names></name><degrees>MD</degrees><degrees>MSc</degrees><xref rid="noi240047aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kasner</surname><given-names initials="SE">Scott E.</given-names></name><degrees>MD</degrees><degrees>MSCE</degrees><xref rid="noi240047aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Elkind</surname><given-names initials="MSV">Mitchell S. V.</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="noi240047aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="noi240047aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tirschwell</surname><given-names initials="DL">David L.</given-names></name><degrees>MD</degrees><degrees>MSc</degrees><xref rid="noi240047aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Longstreth</surname><given-names initials="WT">W. T.</given-names><suffix>Jr</suffix></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="noi240047aff8" ref-type="aff">
<sup>8</sup>
</xref><xref rid="noi240047aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kronmal</surname><given-names initials="RA">Richard A.</given-names></name><degrees>PhD</degrees><xref rid="noi240047aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beyeler</surname><given-names initials="M">Morin</given-names></name><degrees>MD</degrees><xref rid="noi240047aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="noi240047aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Elm</surname><given-names initials="J">Jordan</given-names></name><degrees>PhD</degrees><xref rid="noi240047aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zweifler</surname><given-names initials="RM">Richard M.</given-names></name><degrees>MD</degrees><xref rid="noi240047aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tarsia</surname><given-names initials="J">Joseph</given-names></name><degrees>MD</degrees><xref rid="noi240047aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cereda</surname><given-names initials="CW">Carlo W.</given-names></name><degrees>MD</degrees><xref rid="noi240047aff14" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bianco</surname><given-names initials="G">Giovanni</given-names></name><degrees>MD</degrees><xref rid="noi240047aff14" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Costamagna</surname><given-names initials="G">Gianluca</given-names></name><degrees>MD</degrees><xref rid="noi240047aff15" ref-type="aff">
<sup>15</sup>
</xref><xref rid="noi240047aff16" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Michel</surname><given-names initials="P">Patrik</given-names></name><degrees>MD</degrees><xref rid="noi240047aff17" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Broderick</surname><given-names initials="JP">Joseph P.</given-names></name><degrees>MD</degrees><xref rid="noi240047aff18" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gladstone</surname><given-names initials="DJ">David J.</given-names></name><degrees>MD</degrees><xref rid="noi240047aff19" ref-type="aff">
<sup>19</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kamel</surname><given-names initials="H">Hooman</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="noi240047aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="noi240047aff20" ref-type="aff">
<sup>20</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Streib</surname><given-names initials="C">Christopher</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="noi240047aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="noi240047aff1"><label>1</label>Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, New York</aff><aff id="noi240047aff2"><label>2</label>Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York</aff><aff id="noi240047aff3"><label>3</label>Department of Neurology, University of Minnesota, Minneapolis</aff><aff id="noi240047aff4"><label>4</label>Division of Hematology and Oncology, Department of Medicine, University of Vermont Larner College of Medicine, Burlington</aff><aff id="noi240047aff5"><label>5</label>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia</aff><aff id="noi240047aff6"><label>6</label>Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York</aff><aff id="noi240047aff7"><label>7</label>Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York</aff><aff id="noi240047aff8"><label>8</label>Department of Neurology, University of Washington, Seattle</aff><aff id="noi240047aff9"><label>9</label>Department of Epidemiology, University of Washington, Seattle</aff><aff id="noi240047aff10"><label>10</label>Department of Biostatistics, University of Washington, Seattle</aff><aff id="noi240047aff11"><label>11</label>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland</aff><aff id="noi240047aff12"><label>12</label>Department of Biostatistics, Medical University of South Carolina, Charleston</aff><aff id="noi240047aff13"><label>13</label>Ochsner Neuroscience Institute, Ochsner Health, New Orleans, Louisiana</aff><aff id="noi240047aff14"><label>14</label>Department of Neurology, Neurocenter of Southern Switzerland EOC, Lugano, Switzerland</aff><aff id="noi240047aff15"><label>15</label>Stroke Unit, Fondazione IRCCS Ca&#8217; Granda Ospedale Maggiore Policlinico, Milan, Italy</aff><aff id="noi240047aff16"><label>16</label>Neurology Unit, Fondazione IRCCS Ca&#8217; Granda Ospedale Maggiore Policlinico, Milan, Italy</aff><aff id="noi240047aff17"><label>17</label>Department of Clinical Neurosciences, University of Lausanne, Lausanne, Switzerland</aff><aff id="noi240047aff18"><label>18</label>Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio</aff><aff id="noi240047aff19"><label>19</label>Sunnybrook Research Institute, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, and Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada</aff><aff id="noi240047aff20"><label>20</label>Deputy Editor, <italic toggle="yes">JAMA Neurology</italic></aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> June 6, 2024.</p><p content-type="published-online"><bold>Published Online:</bold> August 12, 2024. doi:<uri content-type="doi">10.1001/jamaneurol.2024.2404</uri></p><corresp id="noi240047cor1"><bold>Corresponding Author:</bold> Babak B. Navi, MD, MS, Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, 420 E 70th St, Room 411, New York, NY 10021 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ban9003@med.cornell.edu">ban9003@med.cornell.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Navi and Kamel had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Navi, Elkind, Tirschwell, Tarsia, Michel, Kamel, Streib.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Navi, Zhang, Miller, Cushman, Kasner, Elkind, Tirschwell, Longstreth, Kronmal, Beyeler, Elm, Zweifler, Cereda, Bianco, Costamagna, Broderick, Gladstone, Kamel.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Navi.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> All authors.</p><p><italic toggle="yes">Statistical analysis:</italic> Zhang, Elm.</p><p><italic toggle="yes">Obtained funding:</italic> Elkind, Tirschwell, Kamel.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Navi, Cushman, Elkind, Tirschwell, Gladstone, Kamel.</p><p><italic toggle="yes">Supervision:</italic> Navi, Elkind, Longstreth, Tarsia, Bianco.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Navi reported receiving grants from the National Institute of Neurological Disorders and Stroke during the conduct of the study; and receiving personal fees from MindRhythm Inc outside the submitted work. Dr Kasner reported receiving grants from Diamedica, Bristol Myers Squibb, Bayer, Daiichi Sankyo, Genentech, and WL Gore, personal fees from AstraZeneca and NovoNordisk, and royalties from UpToDate outside the submitted work. Dr Elkind reported receiving salary from the American Heart Association and royalties from UpToDate outside the submitted work. Dr Tirschwell reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Longstreth reported receiving grants from the National Institute of Neurological Disorders and Stroke during the conduct of the study. Dr Beyeler reported receiving grants from the University of Bern outside the submitted work. Dr Elm reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Cereda reported receiving personal fees from iSchemaView outside the submitted work. Dr Michel reported receiving grants from the Swiss National Science Foundation, Swiss Heart Foundation, and Faculty of Biology and Medicine of the University of Lausanne outside the submitted work. Dr Broderick reported receiving study medication from Novo Nordisk, grants from the National Institute of Neurological Disorders and Stroke and Roche-Genentech, and consultant fees from Basking Biosciences, Brainsgate, and Kroger Prescription Plans Inc outside the submitted work. Dr Gladstone reported receiving grants from Bayer, the Heart and Stroke Foundation of Canada, and the Department of Medicine at Sunnybrook Health Sciences Centre and University of Toronto outside the submitted work. Dr Kamel reported serving on clinical trial steering or executive committees for Medtronic, Janssen, and Boston Scientific; serving on consulting or end point adjudication committees for AbbVie, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and having household ownership interests in TETMedical, Spectrum Plastics Group, and Ascential Technologies outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> The ARCADIA trial was supported by grant U01NS095869 from the <funding-source rid="sp1">National Institute of Neurological Disorders and Stroke</funding-source>. Study drug in kind was provided by the <funding-source rid="sp2">Bristol Myers Squibb</funding-source>&#8211;<funding-source rid="sp3">Pfizer</funding-source> Alliance for Eliquis, and ancillary funding related to laboratory assays was provided by <funding-source rid="sp4">Roche</funding-source>.</p><p><bold>Role of the Funder/Sponsor:</bold> The National Institute of Neurological Disorders and Stroke, Bristol Myers Squibb, Pfizer, and Roche had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.</p><p><bold>Disclaimer:</bold> Dr Kamel is Deputy Editor of <italic toggle="yes">JAMA Neurology</italic> but was not involved in any of the decisions regarding review of the manuscript or its acceptance.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-NOI240047-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2024-08-12T10:00"><day>12</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2024</year></pub-date><volume>81</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">468735</issue-id><fpage>958</fpage><lpage>965</lpage><history><date date-type="received"><day>27</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>6</day><month>6</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>08</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-11 19:26:12.860"><day>11</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright 2024 American Medical Association. All Rights Reserved.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamaneurol-e242404.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamaneurol-e242404.pdf">jamaneurol-e242404.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archneur/fullarticle/10.1001/jamaneurol.2024.2404"/><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-noi240047-1"><title>Question</title><p>What is the optimal antithrombotic strategy for cancer-associated cryptogenic stroke?</p></sec><sec id="ab-noi240047-2"><title>Findings</title><p>In a secondary analysis of 1015 participants with cryptogenic stroke and atrial cardiopathy in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) randomized clinical trial, 137 participants had history of cancer. Among this subgroup, the risk of major ischemic or major hemorrhagic events was nominally but not significantly lower with apixaban compared with aspirin, but analyses were underpowered given small numbers.</p></sec><sec id="ab-noi240047-3"><title>Meaning</title><p>Among ARCADIA trial participants with history of cancer, the risk of major ischemic or hemorrhagic events did not differ significantly with apixaban vs aspirin, but a clinically important benefit of apixaban could not be ruled out.</p></sec></abstract><abstract><sec id="ab-noi240047-4"><title>Importance</title><p>Approximately 10% to 15% of ischemic strokes are associated with cancer; cancer-associated stroke, particularly when cryptogenic, is associated with high rates of recurrent stroke and major bleeding. Limited data exist on the safety and efficacy of different antithrombotic strategies in patients with cancer and cryptogenic stroke.</p></sec><sec id="ab-noi240047-5"><title>Objective</title><p>To compare apixaban vs aspirin for the prevention of adverse clinical outcomes in patients with history of cancer and cryptogenic stroke.</p></sec><sec id="ab-noi240047-6"><title>Design, Setting, and Participants</title><p>Post hoc analysis of data from 1015 patients with a recent cryptogenic stroke and biomarker evidence of atrial cardiopathy in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial, a multicenter, randomized, double-blind clinical trial conducted from 2018 to 2023 at 185 stroke centers in North America. Data analysis was performed from October 15, 2023, to May 23, 2024.</p></sec><sec id="ab-noi240047-7"><title>Exposures</title><p>Oral apixaban, 5 mg (or 2.5 mg if criteria met), twice daily vs oral aspirin, 81 mg, once daily. Subgroups of patients with and without cancer at baseline were examined.</p></sec><sec id="ab-noi240047-8"><title>Main Outcomes and Measures</title><p>The primary outcome for this post hoc analysis was a composite of major ischemic or major hemorrhagic events. Major ischemic events were recurrent ischemic stroke, myocardial infarction, systemic embolism, and symptomatic deep vein thrombosis or pulmonary embolism. Major hemorrhagic events included symptomatic intracranial hemorrhage and any major extracranial hemorrhage.</p></sec><sec id="ab-noi240047-9"><title>Results</title><p>Among 1015 participants (median [IQR] age, 68 [60-76] years; 551 [54.3%] female), 137 (13.5%) had a history of cancer. The median (IQR) follow-up was 1.5 (0.6-2.5) years for patients with history of cancer and 1.5 (0.6-3.0) years for those without history of cancer. Participants with history of cancer, compared with those without history of cancer, had a higher risk of major ischemic or major hemorrhagic events (hazard ratio [HR], 1.73; 95% CI, 1.10-2.71). Among those with history of cancer, 8 of 61 participants (13.1%) randomized to apixaban and 16 of 76 participants (21.1%) randomized to aspirin had a major ischemic or major hemorrhagic event; however, the risk was not significantly different between groups (HR, 0.61; 95% CI, 0.26-1.43). Comparing participants randomized to apixaban vs aspirin among those with cancer, events included recurrent stroke (5 [8.2%] vs 9 [11.8%]), major ischemic events (7 [11.5%] vs 14 [18.4%]), and major hemorrhagic events (1 [1.6%] vs 2 [2.6%]).</p></sec><sec id="ab-noi240047-10"><title>Conclusions and Relevance</title><p>Among participants in the ARCADIA trial with history of cancer, the risk of major ischemic and hemorrhagic events did not differ significantly with apixaban compared with aspirin.</p></sec><sec id="ab-noi240047-11"><title>Trial Registration</title><p>ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT03192215" ext-link-type="uri">NCT03192215</ext-link></p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This secondary analysis of the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) randomized clinical trial compares apixaban vs aspirin for the prevention of adverse clinical outcomes in patients with history of cancer and cryptogenic stroke.</p></abstract><funding-group><award-group><funding-source id="sp1">National Institute of Neurological Disorders and Stroke</funding-source></award-group></funding-group><funding-group><award-group><funding-source id="sp2">Bristol Myers Squibb</funding-source></award-group></funding-group><funding-group><award-group><funding-source id="sp3">Pfizer</funding-source></award-group></funding-group><funding-group><award-group><funding-source id="sp4">Roche</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>